MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.32M
Average 0.99M
MLTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
MoonLake ImmunotherapeuticsNASDAQ: MLTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $13.36M rose 483.2% year over year, ahead of the +203.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 272.0% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +483.2% holds above the trailing-twelve-month pace of +203.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 12.9M USD
- Year-over-year change
- +77.1%
- 4-year CAGR
- +4.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.9M | +77.1% |
| FY2024 | 2024-12-31 | 7.28M | +2.5% |
| FY2023 | 2023-12-31 | 7.11M | -26.4% |
| FY2022 | 2022-12-31 | 9.65M | -11.1% |
| FY2021 | 2021-12-31 | 10.86M | — |
Stock-Based Compensation vs competitors
How MLTX compares with its peers on the latest reported figures
- MLTX's LTM Mar 2026 stock-based compensation of $23.96M is the 5th largest of the 11 companies compared; the peer median is $11.68M.
- Its year-over-year change of +203.5% is the highest of 10, against a peer median of -7.4%.
- Over three fiscal years its annual growth of +10.1% compares with a peer median of +32.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $41.12M | +24.3% | +9.7% | 17.7% | |
| LTM Aug 2026 | $40.66M | +8.7% | +10.5% | 5.8% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $36.4M | -7.4% | +94.0% | 492.0% |
| LTM Jun 2026 | $34.27M | +82.5% | +146.7% | 1800.0% | |
| LTM Mar 2026 | $23.96M | +203.5% | +10.1% | — | |
| LTM Mar 2026 | $12.05M | -2.1% | -6.3% | 144.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | $11.32M | -37.2% | +233.0% | — |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $9.13M | -54.6% | — | — |
| FY2025 | $3.73M | -44.6% | +54.6% | 5821.9% | |
| LTM Mar 2026 | $2.63M | -22.6% | -21.7% | — | |
| FY2025 | $0 | — | — | 0.0% | |
| Peer median (excluding MLTX) | $11.68M | -7.4% | +32.5% | 144.0% | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (53.64M) | (49.97M) | (44.08M) | (121.24M) | (229.1M) |
| Depreciation & Amortization | 4.97K | 12.36K | 13.16K | 1.38M | 2.62M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.86M | 9.65M | 7.11M | 7.28M | 12.9M |
| Change in Working Capital | 4.48M | (1.43M) | (6.22M) | (3.78M) | 19.88M |
| Accounts Receivables | (148.77K) | (68.36K) | (840K) | (1.79M) | (2.03M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.57M | (1.31M) | 0 | 0 | 0 |
| Other Working Capital | 3.06M | (44.8K) | (6.22M) | (2M) | 21.9M |
| Other Non-Cash Items | 13.98M | (4.51M) | 399.51K | (225.71K) | (2.3M) |
| Operating Cash Flow | (35.18M) | (55.89M) | (42.78M) | (116.59M) | (196.01M) |
| Capital Expenditures | (50.71K) | (16.01K) | (284.63K) | (519.52K) | (35K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (42.23M) | (175.73M) | (350.28M) | (265.37M) |
| Sales of Investments | 0 | 9.9M | 150.83M | 145.2M | 468.4M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.71K) | (32.34M) | (25.18M) | (205.6M) | 202.99M |
| Debt Repayment | 15M | (15M) | 0 | 0 | 73.02M |
| Common Stock Issued | 28.27M | 3.79K | 482.45M | 52.54M | 72.98M |
| Common Stock Repurchased | (6.2K) | 0 | 0 | (50) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 134.69M | (2.75M) | (1.23M) | 0 |
| Financing Cash Flow | 43.26M | 119.69M | 479.7M | 51.31M | 146M |
| Effect of Forex Changes | (1.33M) | 8.54K | (75.31K) | 127.97K | 1.11M |
| Net Change in Cash | 6.7M | 31.47M | 411.66M | (270.74M) | 154.09M |
| Free Cash Flow | (35.23M) | (55.91M) | (43.06M) | (117.11M) | (196.04M) |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.